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the assessment of smoking behavior, as CO is rapidly absorbed into the bloodstream when lit
cigarettes or cigars are inhaled. CO testing is a medically important billable outpatient service
that can contribute to sustainability of face to face tobacco use treatment services by clinicians.
This article reviews research on the clinical use of CO testing to provide biomedical feedback in
assessing smoking behavior, educating smokers on tobacco health effects, assisting with
treatment planning, and as a motivational tool to encourage people to become tobacco free.
Further research can focus on how to best incorporate CO testing into clinical practice, including
more research on outcomes and methods to ensure that insurers reimburse for testing and
improved ways to use CO testing to initiate attempts to quit tobacco use, to maintain cessation,
and to prevent relapse. CHEST 2018; 153(2):554-562
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gas that reduces oxygen-carrying capacity in
the blood. CO is produced by oxidation of
carbon-containing compounds, such as those
that occur with combustion of cigarettes or
cigars. When smoke from combustible
tobacco smoke is inhaled, CO is rapidly
absorbed into the bloodstream. Although
environmental sources of CO exist (eg, from
incomplete combustion of carbon, such as
motor vehicle exhaust, pollution, or
malfunctioning furnaces during the
winter1,2), tobacco smoking is the major
source of elevated CO levels in the
bloodstream. In contrast, CO2 is the principal




arbon monoxide; COHb = carbox-
nt carboxyhemoglobin
artment of Family Medicine (Dr Gold-
y-Moffitt), University of North Carolina, 
t Wood Johnson University Hospital 
ille, NJ; and the IQuit Smoking Program 
l Center, Jersey City, NJ.CO testing is considered an easy,
noninvasive, and objective contribution to
the assessment of smoking behavior.3 CO
testing measures the amount of CO in end-
tidal expired breath as a marker for smoking
status, and it is an increasingly important
clinical tool for biochemically assessing and
confirming smoking status and for use in
counseling people who smoke cigarettes to
quit smoking.4,5 CO monitors measure the
amount of CO expired in parts per million
(ppm). The level of CO in ppm in the breath
corresponds to the percent of
carboxyhemoglobin or the percentage of
blood cells carrying CO instead of oxygen.4
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hemoglobin. The percentage of fetal carboxyhemoglobin 
(COHb)can also be calculated using maternal expired 
CO.6 People who smoke cigarettes have higher levels of 
CO in expired breath, and CO monitors report both CO 
and COHb levels.4
As a billable outpatient service in the United States, CO 
testing can contribute to sustainability of face to face 
tobacco use treatment services. CO monitors can 
provide biomedical feedback to assess smoking behavior, 
educate smokers about tobacco health effects, assist with 
treatment planning, and serve as a motivational tool for 
people to become tobacco free. This paper reviews 
current use and research on CO testing in clinical 
tobacco treatment settings.CO Assessment in Clinical Situations
CO testing is used in clinical and research settings as an 
objective noninvasive way to assess smoking behavior.3 
CO levels in expired air are correlated with levels of 
self-reported cigarette or cigar smoking.3 CO has a 
half-life of 5 to 6 hours in the body,7 and CO levels 
return to normal after 24 to 48 hours of not smoking.1
In research studies of people who smoke, CO levels > 10 
ppm in expired breath indicate current smoking, 
whereas CO levels < 10 ppm will often be interpreted as 
evidence of smoking cessation.7-9 CO measurements are 
also used clinically to predict severity of nicotine 
dependence and cravings for people attempting to quit.4 
One study found that CO levels in expired air could 
predict whether smokers with normal lung function had 
smoked in the past 8 hours.7 CO levels at or < 12 ppm 
predicted smoking abstinence in the previous 8 hours.7 
CO testing using these thresholds may not easily 
distinguish occasional smokers from nonsmokers.8 
Therefore, in some clinical settings, a threshold of 6 ppm 
provides additional assurance of complete abstinence.1,10
CO and COHb levels are also determined by several 
endogenous (eg, normal metabolism of heme proteins), 
environmental (eg, exposure to motor vehicle exhaust), 
product (eg, different types of combustible tobacco 
products), medical (eg, certain diseases), and individual 
factors. For instance, different methods of smoking 
tobacco products (eg, hookah, cigars, “little” cigars, and 
chillum [conical pipe] smoking) result in different and 
often higher levels of CO.11 Smoking marijuana will 
elevate exhaled CO.12 Patients with COPD, OSA, or 
asthma, as well as those who live in heavily urbanized 
areas, have higher CO levels, even if they do not 
smoke.8,13,14 To assess smoking behavior in suchpatients, a cutoff point of 10 ppm for patients with
asthma and 11 ppm for patients with COPD has been
proposed.15 Conflicting evidence exists about the
presence of elevated levels of exhaled CO in patients
with diabetes mellitus. One study found that exhaled CO
levels were higher in people with diabetes and correlated
with increases in blood glucose levels.16 A more recent
study found that this was not the case using newer CO
monitors.17 CO levels may be elevated in people with
very high levels of secondhand smoke exposure (eg, in
homes, cars, hookah bars), or exhaust from combustible
materials (eg, a faulty furnace). This includes people
whose occupations expose them to exhaust and smoke,
such as firefighters, toll collectors, tractor drivers, road
asphalt workers, and those who spend time along roads
or in heavily polluted urban areas.13,18
Individual differences can also affect CO levels. For
instance, a reduced effort (due to respiratory muscle
fatigue or lack of desire, motivation, or ability to inhale
and exhale deeply) will reduce CO levels.19
Hyperventilation and exercise can also lower CO
levels.20 Although these factors may make it more
difficult to make comparisons of CO levels across
patients, consistently elevated levels within individual
patients who use combustible tobacco products likely
demonstrates higher exposure to the toxicity of these
products.8,10,18 Even if a clinician makes an adjustment
for those with heavy environmental or endogenous
exposure, the most frequent reason for a CO level to be
high in someone who previously smoked is that they
have returned to smoking, either socially or more
heavily.18 Some patients may be resistant to telling their
providers they have returned to smoking out of fear of
disappointment, judgment, or even shame.21
Higher levels of CO and nicotine in the blood may even
correlate with the nature of smoking behavior. For
example, depth of inhalation, number of puffs, and other
measures of smoking topography can affect CO levels as
much as the number of cigarettes smoked.4,22 Some
people reduce the number of cigarettes they smoke but
smoke them more efficiently, resulting in similar CO
levels.4,23 CO levels fluctuate throughout the day,
increasing after each cigarette and decreasing between
cigarettes.7,23,24 The effectiveness of some medications
or products marketed as cessation aides can be assessed
using CO testing. For instance, some have used CO
testing to assess quitting of combustible tobacco
products among groups of subjects who have switched
to vaping and electronic cigarettes.25 Even though a
patient continues to smoke and use nicotine
replacement therapy or other pharmacotherapy for 
smoking cessation, such medications can bring about a 
reduction in expired CO.4 In one study of patients using 
varenicline, regardless of the number of cigarettes 
smoked at the time, a decrease in CO in expired air was 
significant in predicting future abstinence from 
smoking.4 In another study, reductions in cigarettes per 
day, aided by nicotine replacement therapy, were 
verified by reductions in expired CO.26 Increasingly, 
some physicians, such as orthopedic surgeons, require 
smoking cessation prior to major elective surgery, 
such as joint replacement, and use CO measures to 
document abstinence.27
CO Testing and Patient Education in 
Tobacco Use
CO testing can facilitate patient education about the 
effects of smoking, as it is a personalized measurement 
of how smoking affects the oxygen-carrying capacity of 
the blood.4 Although some people are aware of CO and 
its negative health effects, the personalized measure of %
COHb demonstrates that they may be experiencing, or 
are at risk for, those effects.6 Testing can offer “seeing is 
believing” feedback on one consequence of smoking, 
decreased oxygen capacity, which can be related to 
fatigue, low energy, shortness of breath, windedness, and 
other cardiovascular symptoms.6,28 As patients reduce 
tobacco use, clinical experience shows that regular CO 
testing can build patient confidence, especially when 
increased oxygen levels are linked with better breathing 
or higher energy levels.29 This clinical experience “of 
beating the machine” and having very low CO readings 
becomes a metaphor for breaking free of tobacco 
addiction while sustaining quantitative and tangible 
clinical progress.
CO testing may be particularly useful in several 
specialized settings outside the primary care clinic. For 
instance, those with comorbid smoking and mental 
health conditions often smoke at much higher rates than 
the general population; in such patients, the regular use 
of CO testing has increased patients’ knowledge of CO 
and its effects.28 CO monitors are also used outside the 
clinic in health fairs or other public health settings 
because they are portable and noninvasive. Some CO 
monitors automatically convert COHb into fetal COHb, 
which could be useful in providing education for 
pregnant women in any clinical setting.30 The 
development of phone applications and other 
technology that can incorporate CO testing represents 
an opportunity for further patient education.31CO Testing and Motivation for Smoking
Cessation
CO testing may be particularly useful to consider as an
adjunct to behavioral strategies to increase motivation to
quit smoking. Such testing should be of interest to not
only primary care clinicians but also specialists, such as
pulmonologists and cardiologists, who see high numbers
of patients who smoke.32 Tobacco treatment specialists
already regularly use CO testing in face to face treatment
settings to emphasize the benefits of reduced CO
measures, even from one day of abstinence.
CO testing may also motivate repeated attempts to quit
smoking in those who continue to smoke.30 CO testing
should work best when combined with counseling and
other forms of support.29 A study of behavioral change
techniques used in English smoking cessation programs
found that programs that included CO testing tended to
have better quit rates, and the great majority of the
participants in the United Kingdom’s National Health
Services Smoking Cessation Centers receive CO
testing.33 One small study, using CO testing without
counseling, showed that using the CO monitor regularly
for 2 weeks increased the motivation to quit as well as
decreased smoking.34 A randomized controlled trial of
CO testing and feedback with brief counseling,
compared with brief counseling alone, showed increased
threat appraisal and intention to stop smoking in the
next month for those who received CO testing.35 In
addition, participants with high self-efficacy who
received CO testing demonstrated higher rates of
cessation.36 A qualitative study of those receiving
counseling by tobacco treatment specialists reported that
CO testing was believable, helped them understand the
impact of smoking on their health, and was motivational
for them in attempts to quit.37 In contrast, a randomized
controlled trial of CO testing did not show statistically
significant improved outcomes for long-term
motivation,35 and a review of a small number of studies
of biomedical feedback, including CO testing, indicated
that there was insufficient research to fully determine the
impact of CO testing on cessation outcomes in routine
clinical practice.7
Some groups may receive more benefit than others from
routine CO testing.26 For instance, a qualitative study of
pregnant women reported that visual feedback from CO
monitoring offered routinely at the time of an antenatal
ultrasonographic examination improved their
motivation to quit.38 Other studies have examined the
feasibility of self-monitoring CO levels through the
Internet or smart phones to assist individuals with 
cessation. One study of mobile phone CO monitors 
found them to be effective in determining current 
smoking status.31 Another study combined CO testing 
with an Internet intervention, with rewards contingent 
on lower CO levels as a way to increase smoking 
cessation.39 During the period of CO testing, abstinence 
increased, but at 3- and 6-month follow-ups, those who 
had used CO testing were not more likely to be abstinent 
than the control group.40 This research, however, was an 
Internet-based study, paid participants to quit, and did 
not use CO as part of face to face treatment. Further 
research, particularly studies with high methodological 
rigor and larger sample sizes, is necessary to see how CO 
testing, in collaboration with other technologies, can 
best increase motivation and outcomes in smoking 
cessation.29,39Purchasing and Using a CO Monitor
Numerous CO monitors are available, with varying 
accuracy levels.40 Although each model is slightly 
different, they are easy to use and require minimal 
maintenance.30,41-50 Most need to be calibrated about 
twice a year to maintain accuracy and avoid false 
readings. Wiping monitors and changing mouthpiece 
mounts are standard infection control measures that 
may help prevent infections.44,45,49,50 Most CO monitors 
work similarly, but instructions vary slightly in 
procedure. Some of the most commonly used CO 
monitors for tobacco treatment settings are the Bedfont 
Smokerlyzer, the MicroCO Meter, and the BreathCO 
Monitor from Vitalograph. Other monitors exist for use 
in emergency settings or for children. ToxCO by 
Bedfont is one such monitor.47 The price range for 
purchase is considerable (range $60-$1,200) and varies 
in large part based on what is included with the purchase 
and maintenance. A comparison of commonly used CO 
monitors can be found in Table 1, and a protocol of use 
in one tobacco treatment program is seen in Appendix 1.
CO testing requires the active participation of the 
patient. As part of the standard protocol, patients are 
asked to take a deep breath and hold it for 15 seconds 
before making a seal of the disposable mouthpiece and 
exhaling. For patients who may have pulmonary or 
cardiac disorders (eg, COPD, asthma, heart failure) the 
breath is held for as long as they are able before exhaling.
The sensitivity and specificity (Table 1) of different 
monitoring devices vary.41 Since any exposure to CO 
will be measured, secondhand smoke exposure orexposure in home or work heating systems or vehicle
exhaust, as well as any other substance smoked (eg,
marijuana), will need to be considered, especially for
those who report abstinence but have higher readings.18
Calibration and Sanitation
All CO monitors have similar calibration and cleaning
guidelines.30,41-50 All monitors have detachable tubes
that catch CO, preventing the exhaled air from being
inhaled again. The tubes have various names: D piece, T
valve, and mouthpiece adapter. Manufacturers
recommend following standard cleaning instructions,
including regularly replacing the tubes, usually once a
month. Most monitors use disposable cardboard mouth
pieces to attach to the tube. A new cardboard
mouthpiece must be used for each CO test. Some
monitors (eg, piCO Smokerlyzer) have moved to plastic
rather than cardboard mouthpieces. Most of the
monitors require recalibration with a kit every 6 months.
Some of the monitors remind the user when a
calibration or tube change is due. Having the proper
accessories, calibration, and sanitation practices is
essential to accurate readings, and maintenance of the
device.
Practical Issues to Consider in Billing for CO
Testing (ie, Expired Gas Collection)
CO testing is a billable outpatient face to face service in
the United States under the name expired gas collection.
The Current Procedural Terminology code for this
service is 94250, or expired gas collection, quantitative,
single procedure. Under the International Classification
of Diseases, tenth revision, regulations in the United
States, diagnoses that support medical necessity for this
Current Procedural Terminology include most common
tobacco-related pulmonary (eg, asthma), cardiac (eg,
heart failure), and infectious (eg, chronic bronchitis)
conditions; many other common symptoms of smoking
(eg, cough, wheezing, and shortness of breath); and even
abnormal lung findings on examination.51 Although
reimbursement for procedural services is a function of
insurance plan details and varies widely, coverage for
CO testing in clinical situations should proceed in a
manner similar to reimbursement for other pulmonary
diagnostic testing and therapies, such as fractional
exhaled nitric oxide.52 Reimbursement rates in the
United States in 2017 for CO testing average close to
$3053 and may range from around $20 for Medicaid to
> $60 for some private insurance companies. Although
tobacco cessation services (individual/group) have been
TABLE 1 ] Brands and Characteristics of CO Monitors
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CO ¼ carbon monoxide; LCD ¼ liquid crystal display; %COHb ¼ percent carboxyhemoglobin; %FCOHb ¼ percent fetal carboxyhemoglobin; ppm ¼ parts per million.
reimbursed as a preventive service and typically covered 
at 100% (ie, no cost sharing [coinsurance, copays, 
deductibles]) for the majority of patients, CO testing is 
typically considered a diagnostic service and therefore is 
usually covered with a small coinsurance patient 
cost-sharing responsibility. As payers may have variable 
reimbursement policies, if the service is denied by an 
insurance plan or is not covered, the financial 
responsibility for unpaid charges would fall to the 
patient.
Limitations to CO Testing
Although CO testing is an objective contribution to the 
assessment of smoking behavior for combustible 
tobacco products (eg, cigarettes, cigars, water pipes), it is 
not a useful tool to measure consumption of 
noncombustible tobacco products. For instance, to 
objectively measure electronic cigarette or smokeless 
tobacco use, other biochemical assessments, such as 
cotinine or nicotine levels, may be indicated, although 
they are not routinely used in clinical practice. In 
patients who use multiple tobacco products (eg, 
cigarettes and electronic cigarettes), CO testing would 
demonstrate exposure to only one product and may 
underestimate exposure to other harmful constituents. 
In comparison with spirometry, CO testing does not 
assess individual pulmonary function, but it is much 
easier to interpret, can be reliably and quickly used by 
staff after training, and is far less expensive as an 
upfront cost.54
Conclusions
CO testing has emerged as an important medically 
indicated and potentially necessary procedure for 
clinicians offering advanced treatment to assist and 
document patient outcomes in smoking cessation. 
Further research can delineate effective ways to 
incorporate CO testing into clinical practice; promote 
CO testing as a standard of care for supporting attempts 
to quit smoking, cessation attempts, and relapse 
prevention; and demonstrate the cost benefit of  
reimbursement for appropriate testing.
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Appendix 1. Carbon Monoxide Testing Sample
Procedure
Purpose: This policy is intended to outline the
procedures for the safe and appropriate use of carbon
monoxide (CO) testing.
Monitor: The CO monitor used in this sample procedure
is the Bedfont Smokerlyzer, used in the University of
North Carolina Nicotine Dependence Program.
Procedure
I. Training: All clinical staff will receive training in the
health consequences of CO and in the proper use of
the carbon monoxide monitor.
II. Procedure
A. Significance of CO as a harmful byproduct of
smoking tobacco is explained to the patient.
B. Procedure is explained or demonstrated and
questions are answered.
C. Counselor hands the CO monitor to the patient.
D. Patient is instructed to take deep breath and hold
for 15 seconds.
E. If patient is unable to hold breath for a full 15
seconds, patient holds breath for whatever length
of time is comfortably tolerable.
F. After 15 seconds, patient makes seal with lips
over the disposable mouthpiece and exhales.III. Equipment maintenance
A. All monitors should be registered with facilities
as indicated by a barcode with an electronic
product code number.
B. Calibration: Monitors will be calibrated at least
every 6 months.
C. Treatment program supervisor ensures that
maintenance is done and documentation is
maintained.IV. Safety/infection control
A. A new disposable cardboard mouthpiece is used
for each person taking the test, as they are designedfor one use only. Mouthpieces fit into a connecting
device (T-piece) to the CO monitor. Each patient
should blow into the disposal cardboard mouth-
piece, which will be disposed of after testing.
B. Disposal mouthpiece will be removed after the
test using a germicidal disposable cloth. Both will
be discarded.
C. The clinician has the discretion of wearing latex
gloves during the CO testing. Gloves should be
available in every clinical office.
D. A T-piece on each CO monitor is used to “trap” a
breath sample between two nonreturn valves.
These valves also stop people "’sucking back” air
through this T-piece. Each T-piece should be
replaced at least each month according to
manufacturer guidelines.
E. After each use, the CO monitor should be wiped
with an antigermicidal cloth.
